Matt Hoffman

The monoclonal antibody is now the second member of the CGRP inhibitor class to be approved by the FDA.

The third-generation, small molecule CGRP antagonist is the second Biohaven migraine therapy to reach human clinical development.

TSC has shown potential to become the first approved therapy for acute stroke, able to be administered in the ambulance.

After its approval in May for pediatric MS, the data displayed its efficacy in comparison to standard therapy.

The director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about the potential of a DHE therapy for acute migraine treatment.

By the open-label extension’s end, those treated with pitolisant showed a decrease in ESS score by 6.2 from baseline.

The co-director of the UPMC’s Center for Endovascular Therapy spoke about the gains that stroke care has made in the last few years.

The idea of marijuana as a panacea for neurologic conditions has come into play, leading to a need for clarification about the use of CBD for these conditions.

Study findings revealed that AED clearance significantly changes by the first trimester for levetiracetam and by the second trimester for oxcarbazepine and topiramate.

As a phase III trial of DHE gets underway, the director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about its clinical history in the United States.

A real-world study in relapsing MS helped develop a risk score scale to aid in disability progression prediction, and thus, treatment strategies.

Xenon Pharmaceuticals announced the expansion of its ion channel pipeline as a result of feedback from the FDA.

The director of the Epilepsy Program at the Banner University Medical Center spoke about the needs in patient populations with epilepsy.

Also known as S48168, it was previously granted Orphan Drug designation as well as a Rare Pediatric Disease designation in 2015 for Duchenne Muscular Dystrophy.

The approval was based on bioavailability studies which compared the tablet formulation of riluzole to the oral suspension formulation.

The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai discussed the misdiagnosis of the rare condition.

The dual-therapy regimen will be compared to high-dose tPA monotherapy, the standard of care, in patients with distal blood clots post-stroke.

Previously, in a 5-year phase I-II trial, the rAAV vector serotype rh.10 showed promising safety data.

The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai spoke about the treatment options for CIDP.

With the pending decision on 2 more CGRP agents, the need for biomarkers to identify responders has never been greater.

David Dodick, MD, a neurologist at Mayo Clinic who’s been involved with multiple trials of headache medicines, provided further insight into the medication class.

A meta-analysis revealed a history of stroke increases dementia risk by around 70%, and recent strokes more than doubled the risk.

The neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic touched on the therapy’s performance in a phase II clinical trial.

Despite supportive preclinical data, no evidence showed that dextroamphetamine in combination with physiotherapy leads to improvement in post-stroke recovery.

Jeffrey Allen, MD, spoke about the breakthrough barrier in CIDP and the importance of the guidelines for diagnosis.

The small molecule slowed atrophy by roughly 2.5 mL less brain-tissue loss compared to placebo.

What are the best available options for patients with CIDP, and what is still missing?

A subcutaneous intrathecal catheter delivery system has proven safe and tolerable in a preliminary investigation in patients with SMA.

The director of the ALS Clinic at Massachusetts General Hospital pointed to the robust pipeline and meaningful gains in knowledge about the disease as reason to be hopeful.

The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia said that for these patients, there are still many questions without answers.